LCTX Net Income Growth
Lineage Cell Therapeutics, Inc. Common Stock · Net Income Growth
LCTX Net Income Growth
Year-over-year change vs the same period a year earlier
Latest reported21.14%period ending
LCTX TTM Net Income YoY % (-20.00% → 21.14%)
Year-over-year change
High-resolution chart · PNG
LCTX net income growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | Net Income Growth |
|---|---|
| 21.144% | |
| -296.1866% | |
| -241.4101% | |
| -236.4179% | |
| -69.1404% | |
| 31.4931% | |
| 13.3901% | |
| 12.8073% | |
| -9.8211% | |
| -0.416% | |
| 18.2202% | |
| 52.841% | |
| 56.5284% | |
| 51.6144% | |
| 38.9241% | |
| -307.7449% | |
| -324.5977% | |
| -256.271% | |
| -108.3249% | |
| 55.8407% | |
| 66.7706% | |
| 77.0002% | |
| -76.3515% | |
| 47.9427% | |
| -215.642% | |
| -204.4841% | |
| 74.5401% | |
| 28.4945% | |
| 124.7663% | |
| 142.8184% | |
| -130.2263% | |
| -255.6504% | |
| -296.6374% | |
| -232.8651% | |
| -159.5232% | |
| 85.9511% | |
| 425.0905% | |
| 285.6164% | |
| 171.5437% | |
| 157.2325% | |
| 49.3123% | |
| -39.7943% | |
| -28.6759% | |
| 3.1814% | |
| 16.31% | |
| 12.9704% | |
| 16.9304% | |
| -50.1278% | |
| -76.0517% | |
| -83.1413% | |
| -104.8426% | |
| -46.064% | |
| -34.478% | |
| -31.7169% | |
| -27.9908% | |
| -44.6221% | |
| -27.8003% | |
| -38.3557% | |
| -49.283% | |
| -110.2915% | |
| -166.8601% | |
| -168.5975% | |
| -117.9759% | |
| 16.0748% | |
| -1.676% | |
| -2.3755% | |
| -36.0469% | |
| -219.6965% | |
| -235.3992% | |
| -254.5358% | |
| -162.8921% | |
| -70.6606% | |
| -3.8716% | |
| 29.8864% | |
| 22.8676% | |
| 24.5935% | |
| 21.1818% | |
| -6.2682% | |
| 10.1063% | |
| 7.339% | |
| 5.4613% | |
| 15.8196% | |
| 32.7704% | |
| 31.9876% | |
| 6.5414% | |
| 17.6513% | |
| -77.1064% | |
| -63.261% | |
| 18.8744% | |
| 8.8511% | |
| 38.7657% | |
| 28.6201% | |
| 5.0957% | |
| 13.7886% | |
| 20.9116% | |
| 33.164% | |
| 30.6436% | |
| 26.4438% | |
| 26.9617% | |
| 24.8211% |